What key infrastructure and procedural steps should health systems take before administering amyloid-targeting therapies, such as ensuring access to infusion centers, updating workflow, and training existing staff or hiring new staff (for example, a neuroradiologist)?
How do you discuss the risk-benefit profile of the amyloid-targeting therapies with patients and their caregivers, including adverse event considerations, adherence to treatment, travel to the infusion center, etc?
The action is based on phase 3 VOLGA results, which were presented at the ESMO Congress 2026. They support a perioperative regimen that limits the antibody-drug conjugate to 3 cycles before bladder removal.
In this part 2, Kirsten Axelsen, MS, discusses racial disparities, AI in prior authorization, and payers’ readiness for the next wave of CLL therapies.